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Abstract: Anxiety disorders (ADs) are the most common type of psychiatric disorders, with a 
mean incidence of 18.1% and a lifetime prevalence of 28.8%. Pharmacologic options studied for 
treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin 
reuptake inhibitors (SSRIs), noradrenergic and speciﬁ  c serotonergic drug (NaSSA) and dual-reuptake 
inhibitors of serotonin and norepinephrine (SNRIs). In this context, the development of SNRIs 
(venlafaxine and duloxetine) has been particularly useful. As a dual-acting intervention that targets 
two neurotransmitter systems, these medications would appePar promising for the treatment of ADs. 
The purpose of this review was to elucidate current facts and views about the role of duloxetine 
in the treatment of ADs. In February 2007, duloxetine was approved by FDA for the treatment 
of generalized anxiety disorder (GAD). The results of trials evaluating the use duloxetine in the 
treatment of GAD are supportive on its efﬁ  cacy even if further studies on long-term use are needed. 
Apart from some interesting case reports, no large studies are, to date, present in literature about 
duloxetine and other ADs such as panic disorder, social anxiety disorder, obsessive-compulsive 
disorder and post-traumatic stress disorder. Therefore, the clinical efﬁ  cacy and the relative good 
tolerability of duloxetine may be further investigated to widen the therapeutic spectrum of ADs.
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Introduction
Anxiety disorders (ADs) are the most common type of psychiatric disorders, with a mean 
incidence of 18.1% and a lifetime prevalence of 28.8% (Kessler et al 2005). ADs results 
in a great economic burden as it was estimated that they account for a $42.3 billion annual 
cost in the United States, with over 50% of the total sum directed towards nonpsychiatric 
medical treatment costs (Greenberg et al 1999). Moreover, Wang and colleagues (2005), in 
the National Comorbidity Survey Replication, pointed out that only about 37% of  patients 
with ADs utilize any form of health services, including psychiatric consultation (13%), 
other mental health practitioners (16%), or primary care physicians (24.3%).
To date, it is well established that patients suffering of AD may also have a high 
comorbidity with mood disorders, with up to 90% of patients experiencing some 
kind of depressive disorder in their lifetime with these two disorders sharing some 
neurobiological mechanisms such as abnormalities in the 5HT1A receptor function 
(Nutt and Stein 2006).
Due the involvement of multiple neurobiological systems, several classes of medica-
tions have been widely used for the treatment of ADs. The main classes include benzo-
diazepines, tricyclic antidepressants (TCA), buspiron hydrochloride, selective serotonin 
reuptake inhibitors (SSRIs), noradrenergic and speciﬁ  c serotonergic drug (NaSSA), 
and dual-reuptake inhibitors of serotonin and noradrenaline (SNRIs) (Goodman 
2004; Gambi et al 2005; Shearer 2007; Sheehan and Sheehan 2007). It has been 
demonstrated that a novel agent acting on GABA neurotransmission, pregabalin, was 
effective in the treatment of generalized anxiety disorder (GAD) (Rickels et al 2005)Neuropsychiatric Disease and Treatment 2008:4(5) 930
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and, in 2006, it was ofﬁ  cially approved in European Union for 
the treatment of GAD. However, some of these drugs do not have 
a favorable proﬁ  le in the long-term treatment of AD. In fact, even 
if benzodiazepines can be useful for the immediate alleviation 
of anxiety, their effectiveness for long-term management 
has been questioned because of concerns about tolerance, 
dependency, and remission rates (Pollack 2001).
The SSRIs are preferred in the treatment of AD because 
of greater safety and tolerability an to date are licensed for 
the treatment of several AD including panic disorder (PD), 
GAD, obsessive-compulsive disorder (OCD), and social 
anxiety disorder (SAD) (Vaswani et al 2003). However, 
despite their favorable proﬁ  le of side effects, these drugs 
may cause some adverse effects that may be problematic for 
some patients such as sexual dysfunction, risk of bleeding, 
hyponatremia, discontinuation symptoms, and increased 
bodyweight (Westenberg and Sandner, 2006; Williams et al 
2006). In fact, it has been reported that patients with AD are 
more sensible to side effects of psychopharmacological treat-
ment (Bandelow et al 2006). Furthermore, although patients 
with GAD respond to SSRIs, the minority of patients actually 
achieve remission with these treatments (Pollack 2001).
In this context, the development of SNRIs (venlafaxine 
and duloxetine) has been particularly useful. As a dual-acting 
intervention that targets two neurotransmitter systems, these 
medications would appear promising for the treatment of 
AD. The purpose of this review was to elucidate current 
facts and views about the role of the novel SNRI duloxetine 
in the treatment of AD.
Methods
Searches of the Medline database from 1988 through January 
2008 and the PsycInfo/Embase database from 1988 through 
January 2008 were conducted, restricted to the English 
language. The search term “duloxetine” was combined 
with “anxiety”, “generalized anxiety disorder”, “obsessive-
compulsive disorder”, “panic disorder”, “phobia”, “social 
anxiety disorder”, and “post-traumatic stress disorder” to 
identify relevant original research and review articles. All cita-
tions were screened, and the full texts of peer-reviewed journal 
articles considered relevant to the purposes of the review were 
obtained. Bibliographies were scanned to locate additional 
relevant publications, even those older than 1988.
Characteristics of duloxetine
Duloxetine [LY248686, (+)-N-methyl-3-(1-naphthalenyloxy)-
2-thiophenepropanamine], a relatively new antidepressant 
drug, was discovered in 1988 by Wong and colleagues 
and released in August 2004. Duloxetine is an inhibitor of 
the reuptake of serotonin (5-hyroxytryptamine; 5HT) and 
noradrenaline (NA), both in vitro and in vivo (Wong et al 
1993). Duloxetine has demonstrated a relatively evenly 
balanced and potent inhibition of both the 5HT and NE 
reuptake at the transport sites and a weak effect on dopamine 
reuptake in both in vitro and in vivo studies (Pitsikas 2000; 
Wong 1998; Wong and Bymaster 2002). Duloxetine lacks 
signiﬁ  cant afﬁ  nity for muscarinic, histamine H1, alpha-
1-adrenergic, dopamine D2, 5HT1A, 5HT1B, 5HT1D, 
5HT2A, 5HT2C, GABA, glutamate and opioid receptors 
(Wong et al 1993; Bymaster et al 2001). Moreover, dulox-
etine does not exert its action through the inhibition of 
monoamine oxidase (MAO).
Duloxetine is rapidly absorbed following oral administra-
tion. Absorption of duloxetine begins two hours after oral 
administration, and the maximum concentration in plasma 
(C-max) is achieved in approximately six hours (Bymaster 
et al 2003). The estimated volume of distribution is 1640 L, 
although there was large variability among subjects (Sharma 
et al 2000). Duloxetine is highly protein bound (96%), 
primarily to albumin or α1-acidglycoprotein (Bymaster 
et al 2003). Duloxetine undergoes extensive metabolism, 
but the major circulating metabolites have not been shown 
to contribute signiﬁ  cantly to the pharmacologic activity of 
duloxetine itself (Westanmo et al 2005). It is metabolized 
primarily by cytochrome P-450 (CYP) isoenzymes 2D6 and 
1A2 (Bymaster et al 2003). Duloxetine has a mean plasma 
half-life of 12 hours (Sharma et al 2000).
Duloxetine was approved by the US Food and Drug 
Administration (FDA) in August 2004 for the treatment of 
major depressive disorder (MDD). It has been suggested 
that, due to a more balanced inhibition of 5-HT and NE 
reuptake, duloxetine can provide enhanced beneﬁ  ts in reliev-
ing depression. It has also been hypothesized that duloxetine 
has less afﬁ  nity for other receptors (eg, muscarinic) that are 
held responsible for the numerous adverse events of other 
antidepressants. Several studies have established the safety 
and efﬁ  cacy of duloxetine in the treatment of MDD (Detke 
et al 2002; Nemeroff et al 2002; Lewis-Fernandez et al 2006; 
Shelton et al 2007). For an exhaustive review of efﬁ  cacy 
and tolerability of duloxetine in MDD see Frampton and 
Plosker (2007).
Moreover, as duloxetine enhances urethral striated 
sphincter activity and increases bladder capacity in an in 
vivo cat bladder irritation model, this SNRI seems to be 
efﬁ  cacious in the treatment of stress urinary incontinence 
(Moore 2004). Duloxetine has not been approved for stressNeuropsychiatric Disease and Treatment 2008:4(5) 931
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urinary incontinence in the USA, but has been approved 
for stress urinary incontinence in the European Union since 
August 2004.
In September 2004 duloxetine was approved for the man-
agement of diabetic peripheral neuropathic pain. Even if the 
exact mechanism of central pain inhibition of duloxetine is, 
to date, not well known, it is thought to be related to potentia-
tion of adrenergic and serotoninergic activity in the central 
nervous system (Wernicke et al 2006).
Rationale for duloxetine 
treatment of ADs
It has been widely demonstrated that MDD is associated 
with altered regulation of both 5-HT and NA neurotransmis-
sion and that acting on these two systems both separately or 
simultaneously may lead to therapeutic effects. Moreover, 
it is also well known that clinical observations demonstrate 
a signiﬁ  cant degree of overlap in symptoms associated with 
MDD and ADs (Baldwin et al 2002). Although the precise 
mechanisms underlying the pathogenesis of anxiety remain 
unclear, a lot of evidences support decreased serotonergic 
function in both depression and anxiety.
Studies conducted on patients suffering of ADs have 
pointed out that a dysregulation of 5-HT neurotransmission 
such as low 5-HT turnover rate, is believed to play a role in 
the manifestation of symptoms of anxiety (Graeff et al 1997; 
Wrase et al 2006). Additionally, there have been reports of 
reduced serotonin transporter (SERT) binding in patients 
with GAD (Iny et al 1994). Consistent with these notions, 
antidepressants that enhance serotonergic neurotransmission, 
such as the SSRIs, have been found to be effective in treat-
ing some ADs, as above speciﬁ  ed. Moreover, several genetic 
studies have demonstrated associations between certain 
polymorphisms in the 5-HT gene and anxiety traits as well 
as GAD (Lesch et al 1996; Ohara et al 1999). In addition, 
the short allele of the 5-HT gene linked polymorphic region 
has been associated with a greater activation of the amygdala 
in response to fearful face stimuli in healthy subjects (Hariri 
et al 2002).
The role of NA in anxiety is less clear, but many lines 
of evidence support the hypothesis that NA neurotransmis-
sion is involved in anxiety (Morilak et al 2005). NA has 
been shown to modulate activity in regions of the brain that 
are involved in anxiety, such as the amygdala and the locus 
coeruleus (Van Bockstaele 2000). In addition, increases in 
3-methoxy-4-hydrophenylglycol (MHPG; a metabolite of NA) 
and hypersecretion of NA in plasma and cerebrospinal ﬂ  uid 
have been associated with anxiety states (Bremner et al 1996). 
Clinical evidences, including results from studies that have 
evaluated the anxiolytic efﬁ  cacy of agents that modulate 
noradrenergic neurotransmission, are consistent with the 
involvement of NA in ADs (Stahl et al 2005).
Also preclinical studies have suggested anxiolytic effects 
for duloxetine. Using the mouse zero maze anxiety model, 
Troelsen and colleagues (2005) compared the effects of 
chronic administration of several antidepressants, including 
tricyclics, SSRIs, and SNRIs. Duloxetine demonstrated a 
signiﬁ  cant anxiolytic effect via reduction in all of the animal 
behaviors associated with anxiety. The chronic duloxetine 
treatment regimen also resulted in a considerable reduction 
in serotonin transporters (SERT) density in the cortex after 
duloxetine whereas citalopram, amitriptyline and reboxetine 
were not anxiolytic after chronic treatment and induced a 
small or no reduction in SERT density.
These findings were also confirmed by Mirza and 
colleagues (2007) who showed that duloxetine and ﬂ  uoxetine 
both reduced SERT density in mice cortex and induced 
anxiolytic-like effects. Moreover, duloxetine also reduced 
noradrenaline transporter (NET) density in mice cortex, with 
increased anxiolytic-like effects.
Moreover, as it has been demonstrated that duloxetine 
may antagonize the p-chloroamphetamine-induced deple-
tion of 5-HT in the rat brain (Wong et al 1993), preventing 
also the depletion of NE induced by 6-hydroxydopamine 
in mice hearts and in the hypothalamus of rats (Fuller et al 
1994), this may account for its action on anxiety symptoms: 
in addition, using microdialysis, it has been shown that 
acute systemic duloxetine administration may cause a large 
increase in extracellular levels of 5-HT and NE especially in 
the hypothalamus and cortex (Engleman et al 1995; Kihara 
and Ikeda 1995). Kasamo and colleagues (1996) found that 
duloxetine inhibits the spontaneous ﬁ  ring of both the dorsal 
raphe 5-HT and the locus coeruleus NE neurons, indicat-
ing an increased availability of these neurotransmitters in 
the immediate vicinity of their somatodendritic receptors 
regulating their ﬁ  ring activity.
The role of duloxetine 
in the treatment of GAD
The course of GAD appears, for its own nature, to require long-
term treatment (Rynn and Brawman-Mintzer 2004). With this 
consideration, SSRIs and selective serotonin and noradrenaline 
reuptake inhibitors (SNRIs) have become ﬁ  rst-line treatment 
interventions (Pollack 2001). The SNRI venlafaxine has been 
approved for GAD by the FDA as was shown to be effective 
in double-blind clinical trials (Rickels et al 2000).Neuropsychiatric Disease and Treatment 2008:4(5) 932
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Efﬁ  cacy of duloxetine on anxiety symptoms, especially 
in the treatment of GAD, has become object of investigation 
starting from the observation that duloxetine was effective in 
reducing anxiety symptoms associated with MDD. Dunner 
and colleagues (2003) analyzed all the placebo-controlled 
studies of duloxetine in MDD but focused on four trials in 
which duloxetine was superior to placebo on the primary 
outcome measure of the Hamilton Depression Rating Scale 
(HAM-D) total score, with anxiety symptoms assessed 
using the HAM-D anxiety/somatization subfactor and the 
anxiety-psychic item (HAM-D Item 10). They concluded 
that duloxetine was effective in treating a broad spectrum 
of symptoms associated with depression, including mood, 
anxiety, and painful physical symptoms. In particular, they 
pointed out that duloxetine caused a rapid relief of anxiety 
symptoms associated with depression. More recently, Fava 
and colleagues (2007) investigated the efﬁ  cacy and toler-
ability of duloxetine in the treatment of anxious versus 
nonanxious depression with anxious depression deﬁ  ned 
by a HAM-D Anxiety/Somatization Factor score 7. They 
observed that duloxetine treatment was associated with 
a signiﬁ  cantly greater reduction in total HAM-D scores 
and HAM-D Anxiety/Somatization Factor scores among 
patients with anxious depression with the latter showing a 
signiﬁ  cantly shorter median time to response than patients 
with nonanxious depression. Moreover, the tolerability of 
duloxetine was comparable between groups.
In February 2007, also duloxetine has been approved by 
FDA for the treatment of GAD and the double-blind, placebo-
controlled, large sample (100 patients) studies of dulox-
etine in the treatment of GAD are summarized in Table 1. 
Overall, all these studies demonstrated that duloxetine was 
more effective than placebo and, at least, equal effective than 
venlafaxine XR in the treatment of GAD. Moreover, Russell 
and colleagues (2007) reported the effectiveness of duloxetine 
in improving not only anxiety symptoms, but also pain sever-
ity and patient functioning in adults with GAD, who presented 
with clinically signiﬁ  cant pain symptoms. Interestingly, the 
data of the study of Hartford and colleagues (2007), Koponen 
and colleagues (2007) and Rynn and colleagues (2008) were 
also analyzed globally in two studies. In the ﬁ  rst, Endicott and 
colleagues (2007) pooled data of these three clinical studies 
to report the efﬁ  cacy of duloxetine in reducing role impair-
ments and in enhancing wellbeing in patients with GAD and 
found that duloxetine consistently reduced role functioning 
disabilities associated with GAD and enhanced patients’ 
quality of life and well-being. In addition, summarizing 
efﬁ  cacy of the same three clinical studies, Allgulander 
and colleagues (2007) concluded that, considering a sample 
of more than 1100 patients, duloxetine was efﬁ  cacious for 
reducing anxiety severity and for increasing patients overall 
role functioning in GAD.
Moreover, Pollack and colleagues (2008), pooling data 
from three double-blind, placebo-controlled clinical trials 
that examined the efﬁ  cacy of duloxetine in GAD (Hartford 
et al 2007; Koponen et al 2007; Rynn et al 2008), found that 
patients with GAD experience signiﬁ  cant and substantial 
impairment in three domains of quality of life: global role 
functioning, subjective well-being, and perceived health. 
Using the criterion of improvement to community values, 
patients treated with duloxetine were more likely to achieve 
this outcome on each quality of life measure.
However, it should be considered that all of the clini-
cal trials were for short-term (9–10 weeks) acute treatment 
and therefore longer trials are necessary to determine the 
extended response and maintenance of effect from duloxetine 
treatment in GAD. To date, there are no long-term studies 
that examined whether the clinical efﬁ  cacy of venlafaxine in 
treating GAD is maintained for 6 months or longer. Moreover, 
as patients with GAD frequently have comorbid psychiatric 
and medical illnesses and these trials excluded signiﬁ  cant 
psychiatric and medical comorbidity, results of these studies 
should be extended also to, for example, primary-care settings 
to adding evidences to the generalizability of result to general 
patient population.
Role of duloxetine in the treatment 
of other ADs
Despite growing evidences about a good efficacy of 
duloxetine in the treatment of GAD, there is a relative 
lacking of data of its potential efﬁ  cacy in other ADs such 
as PD, SAD, OCD, and post-traumatic stress disorder 
(PTSD). In fact, for these disorders, there are only case 
reports that have suggested a potential efﬁ  cacy. Crippa and 
Zuardi (2006) reported a case of a 26-year-old woman with 
PD and agoraphobia successfully treated with duloxetine 
whereas Luis Blay and Black (2007) showed a good 
clinical response in a 38-year-old man with OCD with 
a successful 1-year follow-up. Recently Dell’Osso and 
colleagues (2008) reported the cases of four patients with 
treatment-resistant OCD who were switched from SSRIs to 
duloxetine and followed up for 12 weeks. At the endpoint, 
three out of four patients showed a clinically signiﬁ  cant 
improvement of the OC symptoms (35% on the Y-BOCS 
score), whereas the clinical features of the fourth patient 
remained unchanged.Neuropsychiatric Disease and Treatment 2008:4(5) 933
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De Berardis et al
Again Crippa and colleagues (2007) pointed out that 
duloxetine treatment at 120 mg/day was efﬁ  cacious to reduce 
Brief Social Phobia Scale scores in two women with SAD.
Concerning PTSD, a case report showed an exacerbation 
of PTSD symptoms with use of duloxetine in a 53-year-old 
married Vietnam veteran, but this patient was also affected by 
bipolar disorder and this may potentially explain the ﬁ  nding 
along with sustained noradrenergic effects of this medica-
tion (Deneys and Ahearn 2007). On the other hand, Hanretta 
and Malek-Ahmadi (2007) reported a case of 38-year-old 
woman with treatment-resistant MDD and PTSD who was 
successfully treated with electroconvulsive therapy along 
with a duloxetine–olanzapine combination.
Safety of duloxetine 
in the treatment of ADs
The duloxetine treatment was generally well tolerated in the 
three studies of GAD where data on tolerability were avail-
able (Allgulander et al 2007; Endicott et al 2007). Nausea 
was the most frequent adverse effect reported by the patients 
in the studies of GAD. Treatment groups did not differ 
signiﬁ  cantly in their overall study completion rates, which 
were 64.8% for duloxetine and 68.1% for placebo. The rate 
of discontinuation due to adverse event was 15.6% for the 
duloxetine group (mostly due to nausea and vomiting). No 
signiﬁ  cant effect on weight was reported with the duloxetine 
treatment.
Conclusions
Duloxetine is a promising treatment for ADs that may be 
employed to obtain patient remission than merely response 
(getting the patient 50% better). The emerging data suggests 
that dual action agents may have greater efﬁ  cacy in getting 
the patients with GAD to remission. However, the clinical 
efﬁ  cacy of this drug will be more evident once will be more 
widely prescribed and used in the community by physicians. 
The results of  trials evaluating the use duloxetine in the treat-
ment of GAD are supportive on its efﬁ  cacy on this disorder 
without severe adverse effects. Despite its clinical efﬁ  cacy 
and FDA approval for the treatment of GAD, surprisingly, 
to date, the long term efﬁ  cacy of duloxetine has not been yet 
investigated deeply and therefore further studies on long-term 
period are needed. Apart from some interesting case reports, 
no studies are, to date, present in literature about duloxetine 
and other ADs. Therefore, the clinical efﬁ  cacy and the relative 
good tolerability of duloxetine in other ADs than GAD may 
be further investigated with double blind placebo-controlled 
studies in order to widen the therapeutic spectrum of ADs.
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